CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...

Spanish gene therapy specialist VIVEbiotech has named Patricio Massera as its new president, bringing in a seasoned CDMO ...

Natalia Elizalde, PhD, is chief business development officer for VIVEbiotech, a Spanish CDMO that specialises in lentiviral vector production. Elizalde has specialised in business development in ...

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche's Luxturna and Novartis' Zolgensma.